Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT05270200 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Single Arm Study of Post-transplant Azacitidine and Chidamide for Prevention of Acute Myelogenous Leukemia Relapse

StatusRecruiting
PhasePhase 1/2
Started
View on ClinicalTrials.gov ↗

Record History

  1. Enrollment target: 20 to 40v4
  2. Primary completion date: Feb 1, 2024 to Dec 31, 2027 Completion date: Jul 1, 2024 to Dec 31, 2027 · Study description revisedv3 Show 2 more changesShow less
    • Completion date: Jul 1, 2024 to Dec 31, 2027
    • Study description revised

    See this version in full on ClinicalTrials.gov ↗

  3. Re-verified, no change to tracked fieldsv2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The goal of this clinical research study is to learn if azacitidine combined with Chidamide will help to control the disease in patients with high-risk AML after an allogeneic stem cell transplant. The safety of this combination will also be studied.
Trial Details
NCT Number NCT05270200
Lead Sponsor Zhujiang Hospital
Conditions Leukemia, Myeloid, Acute
Enrollment 40 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov